Please assess the completion status of the following clinical trial:

Trial Title: A Study of Effects of Canagliflozin as Add-on Therapy to Insulin in the Treatment of Participants With Type 1 Diabetes Mellitus (T1DM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must have type 1 diabetes mellitus (T1DM) for at least 1 year~* Must have have inadequate glycemic control (as defined by glycosylated hemoglobin level of \>= 7.0% to \<= 9.0%) on basal plus bolus insulin at screening~* Must have body mass index 21 to 35 kg/m2 inclusive~* Must be on a total daily dose of insulin \>= 0.6 IU/kg at screening~* Must be on a stable insulin regimen for at least 8 weeks prior to screening~Exclusion Criteria:~* History of T2DM, pancreas or β-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy~* Severe hypoglycemia (defined as an event required assistance from another person, or which resulted in seizure or loss of consciousness) within 6 months prior to study start~* Diabetic ketoacidosis within 6 months prior to study start~* History of hereditary glucose-galactose malabsorption or primary renal glycosuria~* An ongoing, inadequately controlled thyroid disorder

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Canagliflozin 100 mg (Type: EXPERIMENTAL): Each participant will receive 100 mg of canagliflozin once daily for 18 weeks.
- Canagliflozin 300 mg (Type: EXPERIMENTAL): Each participant will receive 300 mg of canagliflozin once daily for 18 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Each participant will receive matching placebo once daily for 18 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).